Glycovaxyn received first milestone payment from Janssen

Please login or
register
27.01.2015

GlycoVaxyn, a leader in the development of innovative conjugate vaccines, announced that it has received the first milestone in its clinical co-development with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, of the vaccine candidate aimed to prevent infections caused by Extraintestinal Pathogenic Escherichia coli (ExPEC or E. coli).

“We are excited about the achievement of this clinical milestone in our collaboration with Janssen. This underlines the ability of GlycoVaxyn’s versatile bioconjugation platform to generate novel vaccine candidates, which elicit a robust antibody response. The interim results validate our technology and ability to achieve clinical proof of mechanism within a very short period of time. We believe that the ExPEC vaccine has the potential to become a major breakthrough, mainly against the life-threatening antibiotic resistant ExPEC strains causing bacteremia,” said Dr. Michael Wacker, Chief Scientific Officer at GlycoVaxyn.

The clinical milestone is linked to the achievement of a robust immune-response against all antigens included into the vaccine candidate at 30 days post-vaccination. ExPEC bacteria are a leading cause of adult bacteremia, an increasing problem in the aging population and partly linked to increasing antibiotic resistance. The induction of bactericidal (opsonophagocytic) antibodies, a well-known protective mechanism against bacteremia, is being measured in the ongoing clinical study. The first-in-human, placebo-controlled, randomized multicenter study currently conducted in Switzerland includes 194 women affected by recurrent urinary tract infections (UTIs). The primary aim is to assess the safety and immunogenicity of the vaccine candidate, including the measurement of bactericidal antibodies.

GlycoVaxyn’s versatile, propietary bioconjugation platform enables the conjugation of antigenic polysaccharides to protein carriers and makes the development of complex multivalent vaccines easier, faster and more reliable. Conjugate vaccines have been successfully used over the last four decades to prevent bacterial infections like meningitis and pneumonia and conjugate vaccines account for more than 30% of annual vaccines sales. An ExPEC vaccine is wanted since long and the novel bioconjugation technology can make it possible to prevent adult E.coli bacteremia.

0Comments

More news about

GlycoVaxyn AG

Company profiles on startup.ch

GlycoVaxyn AG

rss